- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07645105
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obesity
The Effect of Body Weight Reduction on Selected Metabolic and Biochemical Parameters in Individuals With Overweight or Obesity
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This was a single-center prospective observational cohort study conducted at the Medical University of Silesia in Katowice, Poland, and in a metabolic outpatient clinic in Miasteczko Śląskie, Poland. The study was designed to evaluate the effect of body weight reduction on selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity.
The study was conducted in the context of routine metabolic outpatient care. Participants with overweight or obesity received standard lifestyle-based body weight reduction management, including individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. The investigators did not assign participants to an investigational medicinal product, medical device, dietary supplement, surgical procedure, pharmacological intervention, or experimental therapy. The study prospectively observed participants receiving routine lifestyle-based weight reduction management and assessed changes in clinical and laboratory parameters before and after body weight reduction.
The approved study protocol planned the inclusion of individuals with overweight or obesity and a normal-weight comparison group. Participants with BMI > 25 kg/m² were evaluated in relation to body weight reduction, while individuals with normal body weight served as a comparison group for selected baseline analyses. Patients with overweight or obesity were assessed by medical examination, dietary and clinical questionnaires, anthropometric measurements, body-composition analysis, and fasting blood sampling. Body-composition analysis included assessment of body weight, fat mass, fat-free mass, skeletal muscle mass, total body water, visceral fat, and related parameters. Blood samples were collected for biochemical analyses, including markers of glucose metabolism, lipid metabolism, oxidative stress, antioxidant status, inflammatory markers, adipokines, cytokines, chemokines, growth factors, and selected cardiovascular-risk parameters.
Participants with overweight or obesity were followed during standard body weight reduction management until clinically relevant weight reduction or achievement of optimal body weight. According to the original study documentation, assessments were planned before the start of weight reduction, after approximately 10% body weight reduction, and after approximately 20% body weight reduction or achievement of target body weight. Follow-up visits included body weight measurements, waist and hip circumference measurements, dietary counselling, education regarding caloric intake, and motivation to continue lifestyle modification.
The primary objective of the study was to assess whether body weight reduction in individuals with overweight or obesity is associated with changes in selected metabolic and biochemical parameters. Secondary objectives included evaluation of oxidative-stress and antioxidant-status parameters, glucose and lipid metabolism, inflammatory markers, adipokines, cytokines, and body-composition changes. The study also aimed to assess relationships between biochemical parameters and body-composition indices before and after body weight reduction.
The study was approved by the Bioethics Committee of the Medical University of Silesia in Katowice, Poland. All participants received information about the study and provided written informed consent before participation. This ClinicalTrials.gov record is submitted retrospectively to meet journal publication requirements and to provide transparent public information about the completed study.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Silesian Voivodeship
-
Miasteczko Śląskie, Silesian Voivodeship, Polonia, 42-610
- Eko-Prof-Med Medical Center, Metabolic Outpatient Clinic
-
Zabrze, Silesian Voivodeship, Polonia, 41-808
- Department of Biochemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Adults aged 18-85 years
- BMI > 25 kg/m²
- Overweight or obesity diagnosed on the basis of medical examination and body-composition assessment
- Participation in routine lifestyle-based body weight reduction management in a metabolic outpatient clinic
- Written informed consent to participate in the study
Exclusion Criteria:
- Lack of informed consent
- Severe hepatic insufficiency
- Severe renal insufficiency
- Severe respiratory insufficiency
- Severe circulatory insufficiency
- Disturbances of consciousness
- Treatment-resistant depression
- Chronic alcohol abuse
- Pregnancy
- History of serious nervous system injury
- Implanted cardiac pacemaker
- Pharmacological treatment affecting glucose and/or lipid metabolism
- Incomplete follow-up or incomplete laboratory data
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Individuals With Overweight or Obesity
Adults with BMI > 25 kg/m² who were receiving routine lifestyle-based body weight reduction management in a metabolic outpatient clinic.
Participants were prospectively observed and assessed before and after body weight reduction.
Assessments included clinical and dietary questionnaires, anthropometric measurements, body-composition analysis, fasting blood sampling, and biochemical, metabolic, oxidative-stress, inflammatory, adipokine, and cytokine measurements.
|
Standard lifestyle-based body weight reduction management received as part of routine metabolic outpatient care.
It included individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits.
Participants were not assigned to this management as part of the study; the study prospectively observed patients receiving routine care and assessed metabolic, biochemical, inflammatory, oxidative-stress, adipokine, cytokine, and body-composition parameters before and after body weight reduction.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Body Weight
Periodo de tiempo: Baseline and after body weight reduction, up to approximately 6 months
|
Change in body weight from baseline to follow-up after routine lifestyle-based body weight reduction management.
|
Baseline and after body weight reduction, up to approximately 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Body Fat Mass
Periodo de tiempo: Baseline and after body weight reduction, up to approximately 6 months
|
Change in body fat mass assessed by bioelectrical impedance analysis and expressed in kilograms.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in Glucose concentration in mg/dl.
Periodo de tiempo: Baseline and after body weight reduction, up to approximately 6 months
|
Changes in fasting glucose.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in total-cholesterol concentration in mg/dl.
Periodo de tiempo: Baseline and after body weight reduction, up to approximately 6 months
|
Changes in total cholesterol concentration.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in malondialdehyde concentration in μmol/l.
Periodo de tiempo: Baseline and after body weight reduction, up to approximately 6 months
|
Change in blood malondialdehyde concentration, assessed as a marker of lipid peroxidation and oxidative stress, from baseline to follow-up after body weight reduction.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in serum IL-6 concentration in pg/ml.
Periodo de tiempo: Baseline and after body weight reduction, up to approximately 6 months
|
Change in serum interleukin-6 (IL-6) concentration from baseline to follow-up after body weight reduction.
IL-6 was measured in serum samples as a marker of systemic low-grade inflammation and expressed in pg/ml.
|
Baseline and after body weight reduction, up to approximately 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sławomir Kasperczyk, Prof, Medical University of Silesia in Katowice
Publicaciones y enlaces útiles
Publicaciones Generales
- Szlachta B, Birkova A, Cizmarova B, Glogowska-Gruszka A, Zalejska-Fiolka P, Dydon M, Zalejska-Fiolka J. Erythrocyte Oxidative Status in People with Obesity: Relation to Tissue Losses, Glucose Levels, and Weight Reduction. Antioxidants (Basel). 2024 Aug 7;13(8):960. doi: 10.3390/antiox13080960.
- Szlachta B, Birkova A, Wielkoszynski T, Gospodarczyk A, Hubkova B, Dydon M, Zalejska-Fiolka J. Serum Oxidative Status in People with Obesity: Relation to Tissue Losses, Glucose Levels, and Weight Reduction. Antioxidants (Basel). 2023 Oct 27;12(11):1923. doi: 10.3390/antiox12111923.
- Zalejska-Fiolka J, Birkova A, Hubkova B, Wielkoszynski T, Cizmarova B, Szlachta B, Fiolka R, Blaszczyk U, Wylegala A, Kasperczyk S, Grzanka A, Marekova M, Toborek M. Successful correction of hyperglycemia is critical for weight loss and a decrease in cardiovascular risk in obese patients. J Nutr Biochem. 2022 Aug;106:109021. doi: 10.1016/j.jnutbio.2022.109021. Epub 2022 Apr 25.
- Zalejska-Fiolka J, Birkova A, Wielkoszynski T, Hubkova B, Szlachta B, Fiolka R, Blaszczyk U, Kuzan A, Gamian A, Marekova M, Toborek M. Loss of Skeletal Muscle Mass and Intracellular Water as Undesired Outcomes of Weight Reduction in Obese Hyperglycemic Women: A Short-Term Longitudinal Study. Int J Environ Res Public Health. 2022 Jan 17;19(2):1001. doi: 10.3390/ijerph19021001.
- Zalejska-Fiolka J, Hubkova B, Birkova A, Velika B, Puchalska B, Kasperczyk S, Blaszczyk U, Fiolka R, Bozek A, Maksym B, Marekova M, Birkner E. Prognostic Value of the Modified Atherogenic Index of Plasma during Body Mass Reduction in Polish Obese/Overweight People. Int J Environ Res Public Health. 2018 Dec 27;16(1):68. doi: 10.3390/ijerph16010068.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos Nutricionales
- Enfermedades metabólicas
- Sobrenutrición
- Peso corporal
- Trastornos del metabolismo de la glucosa
- Resistencia a la insulina
- Hiperinsulinismo
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Signos y síntomas
- Exceso de peso
- Obesidad
- Síndrome metabólico
- Obesidad Abdominal
- Abdominal obesity metabolic syndrome
Otros números de identificación del estudio
- KNW/0022/KB1/19/I/16
- Secondary ID: KNW-1-016/N/7/2 (Otro número de subvención/financiamiento: Medical University of Silesia)
- Secondary ID: KNW-1/109/K/8/Z (Otro identificador: Medical University of Silesia)
- Secondary ID: KNW-1/171/K/9/O (Otro identificador: Medical University of Silesia)
- Secondary ID: PCN-1-049/K/0/O (Otro identificador: Medical University of Silesia)
- Secondary ID: PCN-1-018/K/1/O (Otro identificador: Medical University of Silesia)
- Secondary ID: PCN-1-132/K/2/O (Otro identificador: Medical University of Silesia)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .